Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory

Abstract

Treatment of bacterial infections is increasingly challenged by resistance to currently available antibacterial agents. Not only are such agents less likely to be active today than they were in the past, but their very use has selected for and continues to select for further resistance. Additional strategies for the management of bacterial illnesses must be identified. In this review, bacteriophage-based therapies are presented as one promising approach. In anticipation of their potential expansion into clinical medicine, clinical microbiologists may wish to acquaint themselves with bacteriophages and their antibacterial components and, specifically, with methods for testing them. Here, we reviewed the literature spanning January 2007 to March 2019 on bacteriophage and phage-encoded protein therapies of relevance to clinical microbiology. KEYWORDS bacteriophagesCitation Caflisch KM, Patel R. 2019. Implications of bacteriophage-and bacteriophage component-based therapies for the clinical microbiology laboratory. J Clin

Considerations for the Use of Phage Therapy in Clinical Practice

“…With the double-layer agar method, a bacterium-phage mixture in melted low-concentration agar is spread over a solid agar nutrient medium in a petri dish ( 81 ). The semisolid state of the bacterium-phage layer restricts movement of bacteria and phages.…”

Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa

“…Adoption of phage therapy into human medicine requires phage susceptibility testing to select a phage or phage combinations for individual patients' isolates and to assess potential emergence of resistance to particular phages (19). The susceptibility of two MDR P. aeruginosa strains to bacteriophage was tested by spot test and enumeration of bacteriophage was assessed by a double-layer plaque assay test (20).…”

Development and validation of a miniaturized host range screening assay for bacteriophages

“…Using this chemical reaction, Adaptive Phage Therapeutics, Gaithersburg, MD have developed the Host Range Quick Test™ (HRQT™) under their sole proprietorship. While the HRQT™ had shown to be able to screen 5000 phages against one bacterial strain under 18 hours [51], this method may not be applicable to the majority of laboratories as it requires specific equipment that is not readily available. The HRQT™ also solely measures the kinetics of aerobic bacteria, but not anaerobes.…”